Abstract -Zinc plays a central role in the immune system and has been found to be signifi cantly reduced in people with Down syndrome. The effectiveness of zinc supplementation in people with Down syndrome has been reported with discordant results. A comparison was made between a range of clinical and biochemical variables and zinc levels in 120 individuals with Down syndrome. Two groups of participants, one with normal zinc levels and the second with low zinc levels, were compared on the following measures: growth hormone secretion, IgA and IgG antigliadin antibodies, presence of coeliac disease, T3, T4, fT3, fT4, TSH, hypothyroidism, hyperthyroidism, CD4/CD8 ratio, total immunoglobulins G and subclasses. No signifi cant difference was found between the two groups, except for IgG4 which was, unexpectedly, signifi cantly decreased in the group with normal zinc levels. In conclusion, an impairment of zinc blood level in individuals with Down syndrome does not necessarily impact on the organs and systems evaluated here.
Introduction
The need of zinc for the growth and survival of animals has been known since 1934 (Todd, Elvejheim & Hart, 1934) , but its necessity in human beings was only shown thirty years later (Georges, 1963) . Prasad (1991) published a review of the evidence supporting the existence of zinc defi ciency as a disease in medicine. A range of clinical features has been observed in association with zinc defi ciency.
The mild type appears with minor impairments of the immune system, taste and smell, night blindness, memory defi ciency and decreased spermatogenesis (Walsh, Sandstead, Prasad, Newberne & Fraker, 1994; Zalewski, 1996) . The severe type shows severe immune impairment, frequent infections, pustular-bullous dermatitis, diarrhoea, alopecia and mental disturbances (Walsh et al., 1994; Kay & Tasman-Jones, 1975) . Similar effects are found in animals with zinc defi ciency (Walsh et al., 1994; Zalewski, 1996; Clegg, Keen & Hurley, 1989) . Acrodermatitis enteropatica is the prototype of a disease due to zinc defi ciency. It is a rare genetic disease due to the decreased absorption of zinc which has an autosomal recessive mode of inheritance. Its clinical features are acral hyperpigmented skin lesions, bullous dermatitis, alopecia, lack of eyelashes and eyebrows, poor growth, pancreatic islet cell hyperplasia, lack of thymus, intermittent diarrhoea, lymphoid and splenic plasmocytosis, low zinc in blood and urine, and low alkaline phosphatase in the serum. The main functions of zinc can be inferred from the symptoms of zinc defi ciency. Zinc plays a central role in the immune system and, consequently, in resistance to the infections. Severe zinc defi ciency is associated with damage of epidermal cells (Aggett, 1989) , which is seen in the skin lesions of acrodermatitis enteropatica (Hambidge, Walravens & Neldner, 1977) . Damage of gastrointestinal and respiratory mucosa (Walsh et al., 1994; Solomons, 1988) , involvement of specifi c immune cells, such as polymorphonuclear cells (Weston, et al., 1977; Briggs et al., 1982; Singh, Failla & Deuster, 1994) , natural killer cells (Allen, Perri, McClain & Kay, 1983; Salas & Kirchner, 1987) and the complement cascade (Jepsen, Teisner & Svehag, 1990 ) also occurs. Bjorksten et al. (1980) reported low zinc serum levels in 12 people with Down syndrome, with impaired neutrophil chemotaxis and lymphocyte response to phytohemagglutinin. Two months after supplementation with zinc sulphate, zinc serum levels increased, neutrophil chemotaxis normalised in 11 out of 12 patients and the lymphocyte response to phytohemagglutinin improved. Tukiainen, Tuomisto, Westermarck and Kupiainen (1980) demonstrated that zinc causes a dose-dependent inhibition of 5-hydroxytryptamine uptake in vitro, but zinc supplementation does not lead to signifi cant effects in vivo. Zinc, copper and selenium are essential microelements of the enzymes superoxide dismutase and glutathione peroxidase, whose activities have been reported to be increased in the erythrocytes of people C. Romano, R. Pettinato, L. Ragusa, C. Barone, A. Alberti & P. Failla • Zinc and Down syndrome Down Syndrome Research and Practice 8 (1), [25] [26] [27] [28] with Down syndrome. In a study (Neve, Sinet, Molle & Nicole, 1983) aiming to defi ne the relationships between these three microelements and both enzymes, zinc plasma levels were found to be normal in people with Down syndrome. Subsequently, Annerén reported, through microprobe nuclear analysis and atomic absorption spectrometry, that zinc levels in the erythrocytes (Annerén, Johansson & Lindh, 1985) and serum (Annerén & Gebre-Medhin, 1987) were signifi cantly reduced in people with Down syndrome compared with a control group. The relationship between circulating thymic hormone (FTS) and zinc has been studied by Fabris et al. (1984) . These authors, starting from the baseline of the decreased concentration of FTS and the presence of factors inhibiting the biological activity of FTS in vitro in the plasma of normal individuals aged over 50 years and in the majority of young people with Down syndrome, reported that the use of zinc sulphate in people with Down syndrome produces hormone levels of FTS and fully prevents FTS-inhibiting activity. Such results suggest that the biologically active FTS is the component bound with zinc and that the increasing FTS activity in the elderly and in people with Down syndrome could be the result of modifi cations in the pathway of zinc-dependent activation of FTS, probably associated with zinc-defi ciency. Subsequently, Provinciali (1988, 1991) suggested that there were correlations between the thymus, zinc and neuroendocrine system. Franceschi et al. (1988) gave 1mg/kg/day of Zn++ as zinc sulphate, in two trials of 2 months with a gap of 10 months, to 18 children with Down syndrome and a clinical history of respiratory, ear and skin infections, low plasma levels of FTS, high plasma levels of unbound molecules of FTS and a decreased absolute number of circulating T lymphocytes. After each trial a dramatic increase of plasma levels of FTS, a near complete disappearance of the inactive molecules of FTS, and a signifi cant increase of the absolute number of circulating T lymphocytes occurred, the zinc levels were corrected, the infections decreased and school attendance increased. The decreased number of circulating B lymphocytes and the impaired lymphocyte response to concanavalin A and phytohemagglutinin were not modifi ed. These positive effects were present also in those children with Down syndrome without apparent zinc defi ciency. These results were not confi rmed by Lockitch et al. (1989) , who administered zinc gluconate or placebo alternately for periods of 6 months to a group of 64 children with Down syndrome and obtained an increase up to 150% of the mean concentrations of zinc in the fi rst group, a tendency towards a decrease of days or episodes of cough and fever, but without any effect on other clinical items, or on copper, immunoglobulins and complement serum levels, on the number of lymphocytes, nor on the in vitro response to mitogens. Napolitano, Palka, Grimaldi, et al. (1990) used a therapeutic trial with 1mg/kg/day of zinc sulphate on 22 people with Down syndrome for times ranging from 6 to 9 months. Fifteen out of 22 people reached a higher centile on their growth charts. The mean rate of height growth increased from 23.84 mm/6 months to 40.80 7.68 mm/6 months. Growth hormone (GH) and serum somatomedins increased. Napolitano, Palka, Lio, et al. (1990) showed a decrease of free T3 in 17 people with Down syndrome and subclinical hypothyroidism treated with zinc sulphate, and found 9 people with Down syndrome and low zinc levels whose thyroid function improved with zinc supplementation. Stabile et al. (1991) used zinc sulphate at a dosage of 20 mg/kg/day for 2 months in 38 home-reared children with Down syndrome, 24 of whom had low zinc levels and 14 normal zinc levels. No correlation was found between low zinc levels and the recurrence and/or the intensity of infections. Participants with low zinc levels showed a decreased response to the phytohemagglutinin of peripheral mononuclear blood cells compared with those with normal zinc levels. A signifi cant increase in the synthesis of DNA was obtained after the administration of zinc sulphate orally. Indeed, the lymphocyte response to phytohemagglutinin was normal in all participants up to 6 months since the end of treatment with zinc and decreased in half of the participants 22 months after the end of the treatment. Licastro et al. (1992) reported that 25 children with Down syndrome and low zinc blood levels, high TSH levels and low levels of rT3, reached, after 4 months of treatment with zinc sulphate, normalisation of zinc levels, thymulin, TSH and a signifi cant increase of plasma levels of rT3. After treatment with zinc no difference was found between children with Down syndrome and the 14 control children. Supplementation with zinc was also associated with a decreased incidence of infectious diseases and an increase in school attendance. Licastro, Mocchegiani, Masi and Fabris (1993) and Licastro et al. (1994) subsequently confi rmed such data. It has been shown that zinc supplementation enables DNA repair in lymphocytes of people with Down syndrome (Chiricolo, Musa, Monti, Zannotti & Franceschi, 1993) . Recently, Bucci et al. (1999) examined a group of individuals with Down syndrome who had a reverse correlation between plasma levels of zinc and TSH levels. The TSH high levels of people with low zinc levels were normalised, after six months of zinc sulphate supplementation. Such discordant results in the literature induced us to carry out a project which compared zinc levels with some clinical and biochemical values during a follow-up study of people with Down syndrome in our Institute.
Zinc and Down syndrome

Materials and Methods
A sample of 120 people with Down syndrome (mean age 13 years, age range 0.4 -48.1 years) were submitted to colorimetric assay of zinc levels. Ninety-six (80%) of them showed levels within the normal range, whereas the remaining 24 (20%) had levels below the normal range. Both groups were compared with regard to the following items: growth hormone secretion, IgA and IgG antigliadin antibodies, presence of coeliac disease, T3, T4, f T3, f T4, TSH, hypothyroidism, hyperthyroidism, CD4/CD8 ratio, total immunoglobulins G and subclasses. Each sample distribution was tested for normality, using three tests (Kolgomorov-Smirnov and Lilliefors tests for normality, Shapiro-Wilk's W test). Where normal distributions were 
Results
No signifi cant differences were found between the two groups with regard to growth hormone secretion, IgA and IgG antigliadin antibodies, coeliac disease, thyroid dysfunction, T3, T4, f T3, f T4, and TSH values, CD4/CD8 ratio and total IgG. The subclass IgG4 was signifi cantly lower in the group of participants with normal zinc levels. The distribution in this case differed signifi cantly from normality (Kolgomorov-Smirnov one-sample test: D = .19615, p < .01; Lilliefors test: p < .01; Shapiro-Wilk's W test: W = 0.75116, p < .0001), therefore non parametric tests were conducted. The Wald-Wolfowitz Runs test (Z = -2.52320; p < .02), the Mann-Whitney U test (U = 370.5; Z = -2.08633; p < .05) and the Kolgomorov-Smirnov two-sample test (p < .05) all indicated a signifi cant difference between the two groups.
Conclusion
Our results do not identify any statistically signifi cant difference between low zinc levels and normal zinc levels with regard to the evaluated items. The state of zinc defi ciency, in the sample of people with Down syndrome examined, does not appear to be associated with any dysfunction in growth hormone secretion, proneness to coeliac disease, thyroid function or immune function.
